Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 371

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 371
---
easured by an amount of € 291million . As of December 31, 2023 the liability was remeasured by an amount of € 541million , reflecting the strong success of the US launch of Beyfortus, which led to sales forecasts being revised upward from the initial estimate. The resulting adjustment was recognized within Financial expenses . For territories other than the US (except for China, which is now considered a “major market,” with profits/losses shared 50 /50 with AstraZeneca), the existing agreement between AstraZeneca and Sanofi continues to govern the principal terms of the collaboration: Sanofi recognizes the sales and cost of sales and shares the Alliance’s commercial profits with AstraZeneca. In May 2023, data from the HARMONIE Phase 3b study confirmed that nirsevimab prevents infant hospitalizations due to RSV with consistent and high efficacy. Beyfortus was approved in Europe in November 2022, in the United States in July 2023, and in a number of other countries (including China and Japan) in 2024.

| F-32 | SANOFIFORM 20-F2024 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

D/ Presentation of the financial statements D.1. Significant transactions D.1.1. Significant transactions of 2024 D.1.1.1. Acquisition of Inhibrx, Inc On May 30, 2024 , Sanofi completed the acquisition of Inhibrx, Inc (“ Inhibrx”), adding SAR447537 (formerly INBRX-101) to Sanofi’s rare disease pipeline. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lungs with progressive tissue deterioration. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. The transaction did not meet the criteria for a business combination under IFRS 3, and consequently was accounted for as an acquisition of a group of assets. The acquisition price was $ 2,035million . Of that amount (plus acquisition-related costs), $ 1,885million was allocated to in- process development in respect of SAR447537 and recognized within Other int